ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness
source: pixabay.com

ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness

It was never just about reaching the summit of Aconcagua, the highest mountain in both the Western and Southern hemispheres. For Scott Osleeb, scaling the heights of this remarkable peak…

Continue Reading ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness
Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis
Fotocitizen / Pixabay

Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis
Now Approved: Skyclarys for Friedreich Ataxia
Source: https://unsplash.com/photos/ZHys6xN7sUE

Now Approved: Skyclarys for Friedreich Ataxia

  Until recently, the only therapeutic options for people with Friedreich ataxia were symptomatic and focused on symptom management: mobility aids, surgery, psychotherapy, speech therapy, heart medications, hearing and vision…

Continue Reading Now Approved: Skyclarys for Friedreich Ataxia
Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations
source: pixabay.com

Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations

According to a story from GlobeNewswire, the gene therapy company LEXEO Therapeutics has recently announced that its investigational gene therapy LX2006 has been granted both Orphan Drug designation and Rare…

Continue Reading Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations
LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia
source: pixabay.com

LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia

The FDA grants designations, such as the Rare Pediatric Disease and Orphan Drug designations, to aid in the drug development process. Recently, LEXEO Therapeutics has received these two designations for…

Continue Reading LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia
New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
mcmurryjulie / Pixabay

New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports

A recent announcement in Biospace by Capsida Biotherapeutics and CRISPR Therapeutics of their newly-formed partnership offers renewed hope for amyotrophic lateral sclerosis (ALS) and Friedreich’s Ataxia patients. The companies believe…

Continue Reading New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
RT001 Granted Rare Pediatric Disease Designation for INAD, FA
source: pixabay.com

RT001 Granted Rare Pediatric Disease Designation for INAD, FA

In a press release from late February 2021, biopharmaceutical company Retrotope shared that its lead drug candidate, RT001, received Rare Pediatric Disease designation for the treatment of patients with Friedreich's…

Continue Reading RT001 Granted Rare Pediatric Disease Designation for INAD, FA
How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic
Source: pixabay.com

How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic

An Australian royal commission is investigating claims that children with disabilities are being excluded from online learning, according to The Guardian. They are also looking into issues with the services…

Continue Reading How Children With Disabilities Are Excluded in Schooling During the COVID-19 Pandemic

Patients Recruited for Phase 2 Study of Experimental Friedreich’s Ataxia Treatment

According to a press release from Barcelona-based biotechnology company Minoryx Therapeutics, the Company has completed enrollment for a phase 2 clinical study of its experimental Friedreich's ataxia treatment, MIN-102 (generic…

Continue Reading Patients Recruited for Phase 2 Study of Experimental Friedreich’s Ataxia Treatment
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials
vitalworks / Pixabay

The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials

According to a story from Charcot-Marie-Tooth Disease News, the U.S. Food and Drug Administration (FDA), under the leadership of commissioner Scott Gottlieb, has begun to change clinical trials by accepting…

Continue Reading The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials
I Have a Rare Disease And I Am Crossing Borders
23/02/2016 Pics (C) Huw John, Cardiff. MANDATORY BYLINE - Huw John, Cardiff Alan Thomas from Llanboidy HealthWise Wales, a new project which will inform future generations’ NHS services, to help protect against fatal illnesses. e-mail: [email protected] Web: www.huwjohn.com

I Have a Rare Disease And I Am Crossing Borders

My name is Alan. I cross many borders as a person with a rare disease. These borders are physical, geographical and psychological. Crossing so many borders has earned me the…

Continue Reading I Have a Rare Disease And I Am Crossing Borders